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We developed a colorimetric and chromatographic as-
say for oseltamivir to assess the authenticity of Tamiﬂ  u (F. 
Hoffmann-La Roche Ltd., Basel, Switzerland) because of a 
growing concern about counterfeit oseltamivir. The colori-
metric assay is quantitative and relies on an extractable col-
ored ion-pair complex of oseltamivir with Congo red or bro-
mochlorophenol blue. The reverse-phase chromatographic 
assay uses an alkaline mobile phase with UV detection. 
Both methods were evaluated for variability and selectivity 
and subsequently applied to batches of oseltamivir products 
acquired through the Internet. The Congo red test showed 
greater assay sensitivity, linearity, and accuracy. Colorimet-
ric and chromatographic analysis showed all batches of os-
eltamivir product were within ±15% of the stated amount of 
active ingredient. 
T
he antiviral drug oseltamivir phosphate has been rec-
ommended by Centers for Disease Control and Pre-
vention as an adjunct in the effective treatment and pre-
vention of inﬂ  uenza. Oseltamivir and zanamivir are both 
approved by the Food and Drug Administration (FDA) for 
use in controlling both inﬂ  uenza A and B viruses (1). Os-
eltamivir phosphate is the active ingredient in Tamiﬂ  u (F. 
Hoffmann-La Roche Ltd., Basel, Switzerland) and is avail-
able in capsule and powder form. 
The specter of an avian inﬂ  uenza pandemic has given 
Tamiﬂ  u much notoriety, and anticipation of the potential 
public health threat has prompted a demand for the product. 
Consequently, criminal elements have already begun to 
produce counterfeit Tamiﬂ  u. Recently, US Customs agents 
seized counterfeit Tamiﬂ  u entering the United States (2). 
The bogus products, which contained vitamin C and lacked 
the active ingredient of oseltamivir phosphate, had been 
purchased through the Internet. Although these shipments 
were quickly detected by a joint effort of the FDA and US 
Customs and Border Protection, these products would eas-
ily have gone unnoticed in developing countries, where in-
sufﬁ  cient resources and infrastructure hamper the ability to 
monitor and preserve drug quality. WHO estimates that up 
to 25% of the medicines consumed in developing countries 
are counterfeit or substandard (3).
Simple and affordable colorimetric assays provide 
a practical means to rapidly monitor drug quality in re-
source-poor areas. Because oseltamivir phosphate (Figure 
1) possesses amine groups, the protonated form may act 
as a cationic site for anionic dyes such as Congo red and 
bromochlorophenol blue to produce colored ion-pairing 
complexes. Congo red has been used in colorimetric de-
terminations of chitosan and poly (N-vinyl-2-pyrrolidone) 
while bromophenol blue has been used in colorimetric as-
says for antimalarial drugs (4–6). Therefore, our objective 
was to develop and evaluate a colorimetric technique, as 
well as a high-performance liquid chromatographic method 
(HPLC), to measure the concentration of oseltamivir phos-
phate in pharmaceutical preparations. The HPLC method 
described here was used to validate the colorimetric test. 
To date, there are few published reports of HPLC meth-
ods for measuring oseltamivir. A sensitive HPLC-mass 
spectrometry assay for oseltamivir carboxlate in plasma 
and urine and an HPLC assay for oseltamivir phosphate in 
pharmaceutical preparations have been described (7,8). In 
our study, we validated, compared, and applied colorimet-
ric and HPLC techniques to the testing of alleged Tamiﬂ  u 
product purchased through the Internet.
Methods
Reagents and Apparatus
All reagents were of analytical-reagent grade, and 
deionized water was used for all aqueous solutions. Phar-
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maceutical-grade oseltamivir phosphate was graciously 
donated by Hoffman-La Roche Ltd. We purchased Congo 
red (dye content ≈97%), bromochlorophenol blue sodium 
salt (dye content ≈95%), potassium hydrogen phthalate, 
monobasic potassium phosphate, sodium bicarbonate, and 
sodium hydroxide from Sigma-Aldrich (St. Louis, MO, 
USA); HPLC-grade acetonitrile from Mallinckrodt Baker, 
Inc. (Phillipsburg, NJ, USA); and ethyl acetate from Acros 
Organics (Morris Plains, NJ, USA).
Absorbance measurements were taken using a Spec-
tronic 21 spectrophotometer (Milton Roy, Riviera Beach, 
FL, USA). HPLC analysis was conducted with an Agilent 
1100 Series system (Agilent, Palo Alto, CA, USA) using an 
X-Terra, RP18, 4.6- × 150-mm column (Waters, Milford, 
MA, USA). 
Sample Preparation
The colorimetric and HPLC methods were evaluated 
in terms of linearity, assay precision, and accuracy by using 
pharmaceutical preparations compounded from a mixture 
of lactose, starch, talc, povidone K30, croscarmellose, and 
stearyl fumarate, which contained known amounts of oselta-
mivir phosphate. These inactive ingredients (excipients) are 
those found in the capsule formulation of Tamiﬂ  u (9). The 
excipient mix was kept constant while various ratios of osel-
tamivir phosphate and lactose were added to produce sample 
groups containing 0%, 50%, 80%, 100%, 120%, and 150% 
of the amount of active ingredient normally found in a Tami-
ﬂ  u capsule. The 100% mixture contains 46% of the active 
ingredient and is equivalent to a capsule containing 75 mg of 
oseltamivir base (98.5 mg oseltamivir phosphate). 
We conducted a search for Tamiﬂ  u products on the In-
ternet using the keywords “Tamiﬂ  u,” “prescription,” and 
“cheap or inexpensive.” Approximately 40 online sources 
were compiled and sorted according to price. We acquired 
the 6 cheapest products that did not require a prescription 
and tested for active ingredient by using both colorimetric 
methods and HPLC. All the products were in capsule form 
and allegedly contained 75 mg of oseltamivir base (98.5 
mg oseltamivir phosphate) as described in the package in-
sert. The contents of the entire capsule were deposited into 
a glass vial, and 32.8 mL of water (Congo red test) or 8.2 
mL (bromochlorophenol blue test) of water was added. The 
mixture was vigorously shaken for ≈10 s, allowed to equili-
brate for 10 min, shaken again, and then ﬁ  ltered through 
0.22- or 0.45-μm membranes. The amount of oseltamivir 
per capsule was then determined by using the colorimetric 
and HPLC methods.
Colorimetric Assay
Congo red and bromochlorophenol blue salt were 
evaluated for the colorimetric assay and prepared at a con-
centration of 1 mg/mL in water. For the Congo red test, a 
portion of material from each sample group was weighed, 
and enough water was added to achieve a concentration 
of 6.5 mg/mL. This is equivalent to 3 mg/mL of oselta-
mivir phosphate present in the 100% sample group. The 
ﬁ  ltered sample solution (0.150 mL) was added to a glass 
siliconized tube containing 0.250 mL of Congo red solu-
tion, 0.350 mL of 0.1 M phthalate buffer, pH 4.2, and 3 mL 
of ethyl acetate. The tubes were capped and the mixture 
vigorously shaken for 10 s. After complete phase separa-
tion, the top organic layer (red, if oseltamivir was present) 
was transferred to a 13-mm diameter clean glass tube for 
absorbance measurements at 520 nm. For the bromochlo-
rophenol blue test, the sample was prepared so that the ﬁ  nal 
concentration for the 100% group was 26 mg/mL, which 
is equivalent to 12 mg/mL of oseltamivir phosphate. The 
sample was mixed and ﬁ  ltered as described previously, and 
0.150 mL was added to a siliconized glass tube contain-
ing 0.250 mL of bromochlorophenol blue solution, 0.350 
mL of 0.1 M phosphate buffer, pH 7.0, and 3 mL of ethyl 
acetate. After vigorous mixing and phase separation, the 
top organic layer (blue, if oseltamivir was present) was 
transferred to a 13-mm diameter clean glass tube for ab-
sorbance measurements at 590 nm. Other drugs commonly 
used in developing countries, i.e. aspirin, ampicillin, chlo-
roquine, acetaminophen, amoxicillin, ciproﬂ  oxacin,  qui-
nine, chloramphenicol and erythromycin, were prepared in 
water at a concentration of 2.5 mg/mL and tested using the 
described colorimetric conditions.
HPLC Analysis
We used a mobile phase comprising 30% acetonitrile 
and 70% 0.05 M bicarbonate buffer, pH 10, at a ﬂ  ow rate of 
1 mL/min to achieve component separation while maintain-
ing column temperature at 30oC. Oseltamivir was detected 
by UV absorbance at 254 and 220 nm with a retention time 
of ≈4 min. Injection volume was 2 μL. The limit of detec-
tion was determined from the analyte mass equivalent to 3 
times the baseline noise.
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Figure 1. Structure of oseltamivir.RESEARCH
Results and Discussion
Colorimetric Assay
Optimal formation of the complex is dependent on 
the ionization constants (pKa) as well as solubility charac-
teristics for both the basic drug and acidic dye; therefore, 
optimum complex formation is pH dependent and is char-
acteristic of the analyte being tested. We determined the op-
timum pH for complex formation between oseltamivir and 
Congo red to be 4; the optimum pH for bromochlorophenol 
blue and oseltamivir was 6–7. The absorption spectra for 
the oseltamivir–Congo red complex (maxima 507 nm) and 
oseltamivir-bromochlorophenol blue complex (maxima 
589 nm) are shown in Figure 2. We evaluated selectivity 
of the Congo red assay with other commonly used phar-
maceuticals. Under the described assay conditions, aspirin, 
ampicillin, chloroquine, acetaminophen, amoxicillin, cip-
roﬂ  oxacin, and chloramphenicol produced a clear colorless 
organic phase; quinine and erythromycin showed a very 
faint rose color. Of the drugs tested for speciﬁ  city using the 
bromochlorophenol blue assay, quinine produced a purple 
color, chloroquine a light blue color, and acetaminophen 
a faint yellow color. The selectivity of the assay is a func-
tion of drug solubility in water as well as pH. Oseltamivir 
phosphate is highly soluble in water (9). Because aspirin, 
acetaminophen, amoxicillin, quinine, chloramphenicol, 
and erythromycin are insoluble or slightly soluble in water, 
most of the material was eliminated by ﬁ  ltration before the 
assay was conducted and may have contributed to a color-
less ethyl acetate phase. Therefore, ﬁ  ltration is considered 
necessary because aqueous solubility and a pKa confer se-
lectivity of the colorimetric tests with oseltamivir. 
Evaluation of the colorimetric assay for oseltamivir 
carboxylate, the active metabolite of the prodrug oseltami-
vir phosphate (9), has not been performed. Ion-pairing with 
acidic dyes under the described conditions is less likely be-
cause the carboxy metabolite is a zwitterion. 
Table 1 shows the intraday and interday variability as-
sociated with the colorimetric assays; Figure 3 illustrates 
the linearity of the absorbance versus concentration curve. 
Greater linearity and lesser variability are observed from 
the Congo red assay. Note that the variability also includes 
deviations arising from the preparation of the oseltamivir 
formulations. The greater slope associated with the Congo 
red curve relative to the bromochlorophenol blue curve in 
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Table 1. Accuracy and precision for the high-performance liquid chromatographic (HPLC) and colorimetric assays (n = 5) 
Accuracy, %  Precision, % 
Nominal concentration, mg/mL         Interday Intraday  Interday Intraday 
HPLC
 0.6  –10.8 –10.3 9.0 7.9
 1.5  –8.4 0.4 7.3 2.3
 2.4  5.0 –0.7 7.3 5.7
 3.0  0.4 1.6 4.9 4.8
 3.6  0.7 4.4 4.1 3.6
 4.5  –0.9 –3.2 2.5 2.5
Congo red colorimetric  
 1.5  2.0 2.2 12.5 2.3
 2.4  2.6 –0.3 9.2 6.9
 3.0  –5.5 1.0 6.5 5.4
 3.6  0.7 1.2 3.7 3.8
 4.5  1.0 –0.1 2.6 1.3
Bromochlorophenol blue colorimetric  
 6.0  –5.3 –19.4 18.6 12.4
 9.6  0.0 3.4 13.5 2.6
 12.0  2.7 10.4 6.1 5.9
 14.4  3.5 3.2 4.3 3.8
 18.0  –2.9 –5.4 4.9 3.0
Figure 2. Spectra of Congo red and bromochlorophenol blue 
complexes with oseltamivir in ethyl acetate.Determination of Oseltamivir Quality
Figure 3 demonstrates a more sensitive assay. The results 
of the colorimetric assays for the oseltamivir phosphate 
products purchased over the Internet are shown in Table 2 
and compared with values determined from HPLC analy-
sis. These values are the percentage of active ingredient 
found per capsule relative to that stated on the manufac-
turer’s package insert. All, except brand B (Cipla), were 
Roche brand products. The senders’ addresses for brands 
C, D, and E were all within the United States, while brand 
C originated from India and brands A and F originated from 
Greece. Except for brand B, all products were within ±10% 
of the stated amount of active ingredient.  
HPLC Analysis
Intraday and interday accuracy and precision were 
within ±10% for oseltamivir phosphate concentrations 
of 0.6 mg/mL to 4.5 mg/mL (Table 1). Mobile phase pH 
above the pKa of a basic analyte generally produces chro-
matograms with a good symmetrical peak shape. The chro-
matogram for oseltamivir is shown in Figure 4. Because the 
pKa of oseltamivir is 7.75 (9), a mobile phase comprising a 
pH 10 (2 U above the pKa) bicarbonate buffer was chosen. 
The C18 column used for the HPLC method is designed to 
operate under basic pH conditions. Injections of aqueous 
mixtures of aspirin, ampicillin, chloroquine, acetamino-
phen, amoxicillin, ciproﬂ   oxacin, quinine, chlorampheni-
col, or erythromycin into the HPLC system showed no 
interfering chromatographic peaks. The limit of detection 
for oseltamivir phosphate at 220-nm and 254-nm detection 
wavelengths are 2.2 ng and 4.2 ng, respectively. 
Conclusions
Anionic dyes such as Congo red and bromochloro-
phenol blue form colored ion-pairing complexes with os-
eltamivir to produce a colored product extractable in ethyl 
acetate. The Congo red method produces a colored product, 
which is more linearly proportional to oseltamivir concen-
tration, has less variability, and is more selective than the 
bromochlorophenol blue method. 
Colorimetric tests are rapid and easy to perform. The re-
agents and equipment for colorimetric tests are inexpensive, 
relatively nontoxic, and are ideal for use in ﬁ  eld situations. 
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